Citations

Showing 10 of 108104 citations.

The state-of-the-art pharmacotherapeutic options for the treatment of chronic non-cancer pain
D’Souza, Ryan S. , Her, Yeng F , Schappell, Justin , Eller, Jennifer , Evans, Timothy C., Hagedorn, Jonathan M. , Langford, Brendan , Wilson, Rachel E, Eller, Jennifer S, Hagedorn, Jonathan M , D'Souza, Ryan S , Wilson, Rachel E.

Mayo Clinic

Expert Opinion on Pharmacotherapy | March 31, 2022 | Volume: 23 | Issue: 7 | Pages: 775-789

10.1080/14656566.2022.2060741 | PMID 35354341 Get It

In It for the Long Haul: Post-Acute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2
Gosser, Rena , Anderson, Sarah , Jen, Christi, Bhatt, Snehal H., Anderson, Sarah, Blaszczyk, Amie Taggart

Mayo Clinic

Journal of Pharmacy Practice | March 31, 2022 | Volume: 36 | Issue: 5 | Pages: 1048-1051

10.1177/08971900221088799 | PMID 35356830 Get It

The COVID-19 pandemic has caused immeasurable clinical, economic, and societal challenges for the world since early 2020. Intense focus has been placed on determining evidence-based acute management of patients infected with the SARS-CoV-2 virus, as well as accelerating vaccination efforts for those eligible to receive it. As patients recover from infection, many are left with long-term symptoms, known as “Long COVID” or “Post-Acute Sequelae of COVID19,” that challenges the ability to fully recover, return to baseline health status, and regain quality of life. As the most accessible healthcare professional, pharmacists can assist with the management of long COVID as a member of the multidisciplinary team. Pharmacists' medication acumen is beneficial to the management of long COVID symptomatology as more research comes to the forefront of this deadly disease.
Effectiveness and safety of SARS‐CoV‐2 vaccine in Inflammatory Bowel Disease patients: a systematic review, meta‐analysis and meta‐regression
Bhurwal, Abhishek , Bansal, Vikas , Arora, Shilpa , Attar, Bashar M. , Minacapelli, Carlos D. , Kochhar, Gursimran , Chen, Lea Ann , Seril, Darren, Mutneja, Hemant , Kochhar, Gursimran S , Chen, Lea Ann , Bansal, Vikas , Mutneja, Hemant , Goel, Akshay , Brant, Steven R

Mayo Clinic

Alimentary Pharmacology & Therapeutics | March 31, 2022 | Volume: 55 | Issue: 10 | Pages: 1244-1264

10.1111/apt.16913 | PMID 35355306 Get It

AbstractIntroductionThere are concerns regarding the effectiveness and safety of SARS‐CoV‐2 vaccine in inflammatory Bowel Disease (IBD) patients. This systematic review and meta‐analysis comprehensively summarises the available literature regarding the safety and effectiveness of SARS‐CoV‐2 vaccine in IBD.MethodsThree independent reviewers performed a comprehensive review of all original articles describing the response of SARS‐CoV‐2 vaccines in patients with IBD. Primary outcomes were (1) pooled seroconversion rate SARS‐CoV‐2 vaccination in IBD patients (2) comparison of breakthrough COVID‐19 infection rate SARS‐CoV‐2 vaccination in IBD patients with control cohort and (3) pooled adverse event rate of SARS‐CoV‐2 vaccine. All outcomes were evaluated for one and two doses of SARS‐CoV‐2 vaccine. Meta‐regression was performed. Probability of publication bias was assessed using funnel plots and with Egger’s test.ResultsTwenty‐one studies yielded a pooled seroconversion rate of 73.7% and 96.8% in IBD patients after one and two doses of SARS‐CoV‐2 vaccine respectively. Sub‐group analysis revealed non‐statistically significant differences between different immunosuppressive regimens for seroconversion. Meta‐regression revealed that the vaccine type and study location independently influenced seroconversion rates. There was no statistically significant difference in breakthrough infection in IBD patients as compared to control after vaccination.ConclusionIn summary, the systematic review and meta‐analysis suggest that SARS‐CoV‐2 vaccine is safe and effective in IBD patients.
The need for rigour and balance in reporting the health impacts of conflict in Tigray, Ethiopia
Masebo, Tsedeke Mathewos, Fikadu, Belayneh Kokebe, Mehari, Enawgaw , Habte, Anteneh, Begna, Kebede H. , Gelaye, Bizu , Mersha, Tesfaye B.

Mayo Clinic

BMJ Global Health | March 31, 2022 | Volume: 7 | Issue: 3 | Pages: e008263

10.1136/bmjgh-2021-008263 | PMID 35361659 Get It

Diagnosis and Management of Barrett's Esophagus: An Updated ACG Guideline
Shaheen, Nicholas J. , Iyer, Prasad G. , Souza, Rhonda F. , Sauer, Bryan G. , Wani, Sachin , Falk, Gary W. , Yadlapati, Rena

Mayo Clinic

American Journal of Gastroenterology | March 31, 2022 | Volume: 117 | Issue: 4 | Pages: 559-587

10.14309/ajg.0000000000001680 | PMID 35354777 Get It

Barrett's esophagus (BE) is a common condition associated with chronic gastroesophageal reflux disease. BE is the only known precursor to esophageal adenocarcinoma, a highly lethal cancer with an increasing incidence over the last 5 decades. These revised guidelines implement Grading of Recommendations, Assessment, Development, and Evaluation methodology to propose recommendations for the definition and diagnosis of BE, screening for BE and esophageal adenocarcinoma, surveillance of patients with known BE, and the medical and endoscopic treatment of BE and its associated early neoplasia. Important changes since the previous iteration of this guideline include a broadening of acceptable screening modalities for BE to include nonendoscopic methods, liberalized intervals for surveillance of short-segment BE, and volume criteria for endoscopic therapy centers for BE. We recommend endoscopic eradication therapy for patients with BE and high-grade dysplasia and those with BE and low-grade dysplasia. We propose structured surveillance intervals for patients with dysplastic BE after successful ablation based on the baseline degree of dysplasia. We could not make recommendations regarding chemoprevention or use of biomarkers in routine practice due to insufficient data.
Management of Patients on Anticoagulants and Antiplatelets During Acute Gastrointestinal Bleeding and the Peri-Endoscopic Period: A Clinical Practice Guideline Dissemination Tool
Barkun, Alan , Douketis, James D. , Laine, Loren , Telford, Jennifer J. , Abraham, Neena S. , Douketis, James, Telford, Jennifer J , Barkun, Alan N , Noseworthy, Peter A.

Mayo Clinic

American Journal of Gastroenterology | March 31, 2022 | Volume: 117 | Issue: 4 | Pages: 513-519

10.14309/ajg.0000000000001688 | PMID 35354773 Get It

Real-World Treatment Strategies to Improve Outcomes in Patients With Chronic Idiopathic Constipation and Irritable Bowel Syndrome With Constipation
Harris, Lucinda A. , Chang, Christopher H., Poppers, David M., Kassebaum-Ladewski, Amy, Sayuk, Gregory S. , Brenner, Darren M. , Waldman, Scott A.

Mayo Clinic

American Journal of Gastroenterology | March 31, 2022 | Volume: 117 | Issue: 4S | Pages: S21-S26

10.14309/ajg.0000000000001709 | PMID 35354772 Get It

Chronic idiopathic constipation and irritable bowel syndrome with constipation are complex, overlapping conditions. Although multiple guidelines have informed healthcare providers on appropriate treatment options for patients with chronic idiopathic constipation and irritable bowel syndrome with constipation, little direction is offered on treatment selection. First-line treatment options usually include fiber and over-the-counter osmotic laxatives; however, these are insufficient for many individuals. When these options fail, prescription secretagogues (plecanatide, linaclotide, lubiprostone, and tenapanor [pending commercial availability]), or serotonergic agents (prucalopride and tegaserod) are generally preferred. Individuals experiencing concurrent abdominal pain and/or bloating may experience greater overall improvements from prescription therapies because these agents have been proven to reduce concurrent abdominal and bowel symptoms. Should initial prescription treatments fail, retrying past treatment options (if not adequately trialed initially), combining agents from alternative classes, or use of adjunctive therapies may be considered. Given the broad spectrum of available agents, therapy should be tailored by mutual decision-making between the patient and practitioner. Overall, patients need to be actively monitored and managed to maximize clinical outcomes.
Burden of Constipation: Looking Beyond Bowel Movements
Harris, Lucinda A. , Chang, Christopher H.

Mayo Clinic

American Journal of Gastroenterology | March 31, 2022 | Volume: 117 | Issue: 4S | Pages: S2-S5

10.14309/ajg.0000000000001708 | PMID 35354769 Get It

Chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C) are associated with significant social and economic burdens. To address these burdens, a deeper understanding of their root causes is required. A discrepancy exists between patients' and healthcare providers' (HCPs) perceptions of constipation symptoms and the impact of symptoms associated with CIC and IBS-C. Compared with the HCPs' perceptions of patients' symptoms, a greater percentage of patients report acceptance and feeling in control of their CIC or IBS-C symptoms. Unfortunately, only one-third of individuals with CIC or IBS-C formally consult an HCP about their constipation. Fewer than half take medications, and these are generally over-the-counter therapies rather than prescription therapies. For those who seek help, only one-fifth feel that their constipation symptoms are well managed. Notable sex and cultural differences exist regarding individuals consulting their HCP about constipation. Many individuals with CIC and IBS-C remain inadequately managed and unduly affected, contributing to the high social and economic burden of these conditions.
Socioeconomic Predictors of Treatment Outcomes Among Adults With Major Depressive Disorder
Mills, Jeffrey A. , Suresh, Vikram, Chang, Lenisa V. , Mayes, Taryn L. , Trivedi, Madhukar H. , Chang, Lenisa, Mayes, Taryn , Strawn, Jeffrey R. , Croarkin, Paul E.

Mayo Clinic

Psychiatric Services | March 31, 2022 | Volume: 73 | Issue: 9 | Pages: 965-969

10.1176/appi.ps.202100559 | PMID 35354325 Get It

Valuable Informal Bereavement Support Strategies for Bereaved Parents of Stillborn, Young Children, and Adult Children: A Scoping Review
Schoonover, Kimberly , Prokop, Larry, Schoonover, Kimberly L, Lapid, Maria I.

Mayo Clinic

Journal of Palliative Care | March 31, 2022 | Volume: 37 | Issue: 3 | Pages: 381-400

10.1177/08258597211062762 | PMID 35354346 Get It

Background: Informal support of a bereaved parent is common after the loss of a child (stillborn, young or adult child); however, it is not clear which aspects of informal support were perceived to be helpful by the bereaved parent. The aim of this scoping review is to clarify from the standpoint of bereaved parents what are considered helpful and unhelpful characteristics of informal support given by the support network of bereaved parents. Methods: A comprehensive search of databases from 2000 to April 20, 2020 was conducted for clinical studies published in English on informal bereavement support of adult bereaved parents of stillborn to adult children; 52 articles met criteria for the scoping review. The databases included Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations, and Daily, Ovid EMBASE, Ovid Cochrane Central Register of Controlled Trials, Ovid Cochrane Database of Systematic Reviews, Ovid PsycINFO, and Scopus. Results: Specific supportive strategies reported by parents as helpful more frequently included talking with other supportive persons felt to be supportive, meeting another person with a similar type of loss, and a loss-specific peer support group. Other support included peer support groups in general, tangible aid, talking with the spouse about the child who died and/or accepting each other's different grieving styles, and remembrance gestures. Specific supportive strategies reported by parents as unhelpful more frequently included feeling of stigma or blame due to type of death or feeling that the type of death was not considered equal to other deaths and platitudes & insensitive comments. Other unhelpful support included talking with others felt to be unsupportive about discussing the loss, others stating a time limit to grief, others actively avoiding or stopping all communication with the bereaved parent, and one spouse not accepting the grieving style of the other or the spouse not willing to discuss the loss. Conclusion: Support focused on supportive verbal and nonverbal communication towards the bereaved parent and tangible aid were noted to be helpful informal support. Feeling stigma for or judged by others due to the type of death or the death not being considered equal (such as in deaths due to suicide and stillborn deaths) to other types of deaths as well as informational support (utilization of clichés/platitudes, advice giving, statements about the process and end point of grieving) were noted to be unhelpful informal support.